Market Size & Share Report, Growth, Trends, 2032

Industry Prospective:

The global pharmaceutical continuous manufacturing market was valued at nearly USD 1.53 billion in 2021 and is expected to rise to just over USD 3.24 billion by 2028, with a CAGR of around 9.6% over the forecast period. The report examines the drivers, constraints, and challenges in the pharmaceutical continuous manufacturing market, as well as their impact on demand throughout the forecast period. The report also looks at new prospects in the pharmaceutical continuous manufacturing market.

Request Free Sample

Pharmaceutical Continuous Manufacturing Market: Overview

Active pharmaceutical substances are manufactured in small, closed units using pharmaceutical continuous manufacturing technology, which makes use of automation. As a result, it needs fewer manual interventions. In a continuous process, production stages that would normally be carried out in a batch process are merged. All of this contributes to the continuous exploitation of industrial capacity. As a result, output variations are reduced, yields are improved, and operating & equipment expenses are reduced. Because of these benefits, the approach is gaining popularity steadily.

COVID-19 Impact:

COVID-19 pandemic positively impacted the growth of the global pharmaceutical continuous manufacturing market. The demand for existing drugs and new active compounds that can aid in the treatment of COVID increased the demand for continuous manufacturing of pharmaceuticals. Also, governments around the world appeal to increase the manufacturing process of drugs during the pandemic period which again supported the market growth. Many pharmaceutical manufacturers remained fully operative during the pandemic period. Besides the sectors faced low restrictions due to their importance during the pandemic period.

Pharmaceutical Continuous Manufacturing Market: Growth Drivers

Advancements in technology and improved process quality may benefit the market growth.

Continuous manufacturing refers to the production of a pharmaceutical product in a single continuous process. The entire procedure takes place in one location, from beginning to end, with no wait times. This helps to lower the manufacturing costs, mostly during the long process run. Further, the technological advances aid to minimize the manufacturing time from weeks to days. The advancement in the process also ensures low human errors that aid in quality improvement. Furthermore, continuous manufacturing is a more agile approach that facilitates production scalability. Scaling up, for example, just entails continuing to run the continuous production process for a longer period. In other words, continuous production makes matching supply to demand much easier than batch manufacturing. Continuous manufacturing also enables tracing and tracking more versatile; for example, instead of a batch being specified by the equipment used in its production, a drug's batch amount might be determined by factors such as time or quantity made. This allows for lower batch sizes, resulting in less waste when flaws are discovered in a batch.

Request Free Sample

Pharmaceutical Continuous Manufacturing Market: Restraints

High process costs associated with continuous pharmaceutical manufacturing may hinder the market growth.

Continuous pharmaceutical manufacturing promises increases productivity at a given time, however, to maintain the continuous process high cost is needed to be invested. Continuous pharmaceutical production is a complex process that needs to maintain many parameters at certain points thus most of the continuous process runs on automation which adds more cost to the overall process. Additionally, as the nature of the process is continuous there is low scope remaining for changing products. Moreover, since a single defect might halt the entire manufacturing process, high receptivity to malfunctions is required. All these factors may hinder the global pharmaceutical continuous manufacturing market growth over the forecast period.

Pharmaceutical Continuous Manufacturing Market: Opportunities

Increasing investments in process automation in pharmaceutical sectors are expected to offer better growth opportunities to the market.

As the demand for new drugs is rising, manufacturers are shifting their mode of process to increase productivity. Continuous production has several advantages, including increased efficiency (productivity, economy), which is enabled by the interconnection of unit operations such as refining, chemical reactions, and crystallization. Improved product quality and safety, which is enabled by continuous automated monitoring of processes. This aid to reduce environmental impact by reducing waste through a high rate of reaction efficiency and space savings due to the compact size of the equipment sets. All these factors support the adoption of automated production systems in the pharma sector. Besides, many major pharmaceutical manufacturers are expanding their API business in emerging countries which will further support the market expansion during the forecast period.

Pharmaceutical Continuous Manufacturing Market: Challenges.

Low adoption of continuous automation process in small and mid-level pharmaceutical companies pose a major challenge for market growth.

The major hindrance to implementing a continuous automation system in a production unit is its cost and complex mechanism. Due to its multiple sensors and operating compartments, a skilled workforce is also required which makes it more tedious to operate. However, such advanced production unit having huge price tag is difficult to set for small-scale manufacturers, which hinders market growth to some extent. Moreover, the number of small-scale drug manufacturers is increasing around the world, in that context the limitations to adopting continuous manufacturing systems by these emerging small-scale manufacturers may limit the market expansion.

Pharmaceutical Continuous Manufacturing Market: Segmentation

The global pharmaceutical continuous manufacturing market is categorized based on product, application, end-user, and region. By product, the market is bifurcated into semicontinuous systems, integrated continuous systems, and control & software. The application segment of the market includes API manufacturing and final drug product manufacturing. The end-user segment of the market is segregated as contract manufacturing organizations, pharmaceutical companies, and others.

Report Scope:

Recent Developments

• September 2021, Thermo Fisher will invest USD 82.5 million to increase production capacity at its biologic drug substance manufacturing facility in St. Louis. The investment will increase the company's entire manufacturing capacity two-fold, serving both short- and long-term COVID-19 requirements.
• September 2021, The Johnson & Johnson manufacturing facility in Ringaskiddy, Ireland, endures to expand. The firm has plans to increase the manufacturing capacity with the completion of a USD 354 million. This investment brings the total amount invested in the biologics production plant to USD 176 million.

Pharmaceutical Continuous Manufacturing Market: Regional Landscape

Europe to lead the global market over the forecast period.

The global pharmaceutical continuous manufacturing market is largely dominated by Europe. Key factors such as the existence of several contract manufacturing organizations, as well as strong demand for innovative technologies from pharmaceutical corporations, have fueled the industry in the region. The United Kingdom and Germany are driving Europe's growth. In 2021, the region holds over 35 percent of the share also in terms of growth, the market in the region is predicted to outperform others, with a CAGR of 9.6% during the forecast period. This is due to the early availability of modern technologies and the increased number of technology suppliers around the area. In terms of market share, Asia Pacific lags behind Europe. The region accounted for around 34 percent of the worldwide pharmaceutical continuous production market in 2021. India and China, which are home to several contract manufacturers, have fueled the market growth in Asia Pacific.

Pharmaceutical Continuous Manufacturing Market: Competitive Landscape

Major players operating in the global pharmaceutical continuous manufacturing market include Coperion GmbH, Bosch Packaging Technology, Gebrüder Lödige Maschinenbau GmbH, Hosokawa Micron Corporation, GEA Group AG, Glatt GmbH, Korsch AG, L.B. Bohle Maschinen + Verfahren GmbH, Thermo Fisher Scientific Inc., and Munson Machinery Company, Inc.

Global pharmaceutical continuous manufacturing market is segmented as follows:

By Product

• Integrated Continuous Systems
• Semicontinuous Systems
• Control & Software

By Application

• Final Drug Product Manufacturing
• API Manufacturing

By End User

• Pharmaceutical Companies
• Contract Manufacturing Organizations
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa